Stemline Therapeutics (NASDAQ:STML) is set to release its earnings data before the market opens on Friday, August 2nd. Analysts expect Stemline Therapeutics to post earnings of ($0.47) per share for the quarter.
Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million during the quarter, compared to analysts’ expectations of $2.61 million. On average, analysts expect Stemline Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Stemline Therapeutics stock traded up $0.07 during trading hours on Wednesday, reaching $13.78. 3,349 shares of the company’s stock were exchanged, compared to its average volume of 322,874. The firm has a market cap of $585.81 million, a price-to-earnings ratio of -4.60 and a beta of 1.33. The stock’s 50 day moving average price is $14.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $17.85.
A number of research firms have recently issued reports on STML. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Roth Capital reissued a “buy” rating on shares of Resverlogix in a research report on Thursday, May 23rd. ValuEngine raised shares of Vermillion from a “hold” rating to a “buy” rating in a research report on Wednesday, May 15th. Zacks Investment Research cut shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright set a $35.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 20th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and an average price target of $23.50.
In related news, COO Kenneth Hoberman sold 25,817 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Ivan Bergstein sold 10,822 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $167,632.78. The disclosure for this sale can be found here. Insiders have sold a total of 149,177 shares of company stock worth $2,236,377 in the last three months. Insiders own 13.10% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: What is Compound Interest?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.